Overview

The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed Conditions

Status:
NOT_YET_RECRUITING

Trial end date:
2024-06-02

Target enrollment:

Participant gender:

Summary

To determine and compare the rate and extent of absorption of a test formulation with that of a reference innovator formulation when given as equal labeled dose in healthy subjects under fed conditions

Phase:

PHASE1

Details

Lead Sponsor:

International Bio service

Treatments:

Metformin
Vildagliptin